Brief: Bridgebio Says FDA Accepts NDA For BBP-418 With Priority Review For LGMD2I/R9
27/05/2026 12:48
BRIEF-Bridgebio Says FDA Accepts NDA For BBP-418 With Priority Review For LGMD2I/R9 May 27 (Reuters) - BridgeBio Pharma Inc BBIO.O:
ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF NDA FOR BBP-418 FOR LGMD2I/R9
FDA ACCEPTS BRIDGEBIO NDA FOR BBP-418 WITH PRIORITY REVIEW FOR LGMD2I/R9
FDA SETS PDUFA TARGET ACTION DATE OF NOVEMBER 27, 2026 FOR BBP-418
FDA NOT PLANNING ADVISORY COMMITTEE MEETING FOR BBP-418 APPLICATION
Source text: ID:nGNX3BhQny
Further company coverage: BBIO.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels